Abstract
Stroke is the third most common cause of death, particularly of the elderly. Despite considerable advances in knowledge about the mechanisms of cell death after stroke, a treatment for stroke remains exclusive. For a long time, estrogen was thought of only as a “sex hormone”. Studies have documented that estrogen plays an important role in regulating behavioral and physiological events beyond the reproductive system. Most animal studies have shown that estrogens exert neuroprotective and neurogenesis effects in vivo and in vitro after ischemic stroke. However, clinical and epidemiological evidence shows that estrogen increases the risk of coronary heart disease, stroke, and breast cancer. The discrepancy between animal studies and clinical data emphasizes the importance of performing further investigations using appropriate animal models, and gaining a deeper understanding of the mechanisms of estrogen-mediated neuroprotection and neurogenesis. This review focuses on recent advances in estrogen-mediated neuroprotection and neurogenesis after ischemic stroke, highlighting its potential molecular and cellular mechanisms
Keywords: Estrogen, ischemia, stroke, neuroprotection, neurogenesis, receptor, Ers, inflammation, oxidative stress, excitotoxicity
Current Drug Targets
Title: Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Volume: 13 Issue: 2
Author(s): Bei Shao, Yifan Cheng and Kunlin Jin
Affiliation:
Keywords: Estrogen, ischemia, stroke, neuroprotection, neurogenesis, receptor, Ers, inflammation, oxidative stress, excitotoxicity
Abstract: Stroke is the third most common cause of death, particularly of the elderly. Despite considerable advances in knowledge about the mechanisms of cell death after stroke, a treatment for stroke remains exclusive. For a long time, estrogen was thought of only as a “sex hormone”. Studies have documented that estrogen plays an important role in regulating behavioral and physiological events beyond the reproductive system. Most animal studies have shown that estrogens exert neuroprotective and neurogenesis effects in vivo and in vitro after ischemic stroke. However, clinical and epidemiological evidence shows that estrogen increases the risk of coronary heart disease, stroke, and breast cancer. The discrepancy between animal studies and clinical data emphasizes the importance of performing further investigations using appropriate animal models, and gaining a deeper understanding of the mechanisms of estrogen-mediated neuroprotection and neurogenesis. This review focuses on recent advances in estrogen-mediated neuroprotection and neurogenesis after ischemic stroke, highlighting its potential molecular and cellular mechanisms
Export Options
About this article
Cite this article as:
Shao Bei, Cheng Yifan and Jin Kunlin, Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke, Current Drug Targets 2012; 13 (2) . https://dx.doi.org/10.2174/138945012799201702
DOI https://dx.doi.org/10.2174/138945012799201702 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Blood Serum Atherogenicity and Coronary Artery Calcification
Current Pharmaceutical Design The Anti-Atherogenic Effects of Thiazolidinediones
Current Diabetes Reviews Utility of Anti-Arrhythmic Medications in ‘Lone Atrial Fibrillation’
Current Pharmaceutical Design The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
Current Vascular Pharmacology Management of Dyslipidemia in the Metabolic Syndrome
Cardiovascular & Hematological Disorders-Drug Targets Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents
Medicinal Chemistry Type 2 Diabetes Mellitus in Saudi Arabia: Major Challenges and Possible Solutions
Current Diabetes Reviews Predicting Protein-Ligand Interactions Based on Chemical Preference Features with its Application to New D-Amino Acid Oxidase Inhibitor Discovery
Current Pharmaceutical Design Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Evidence Base for Revascularisation of Chronic Total Occlusions
Current Cardiology Reviews Oleacein. Translation from Mediterranean Diet to Potential Antiatherosclerotic Drug
Current Pharmaceutical Design New Antimicrobial Approaches: Reuse of Old Drugs
Current Drug Targets Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?
Current Pharmaceutical Design An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Renin Angiotensin System Blockade in the Treatment of Atrial Fibrillation
Current Drug Targets - Cardiovascular & Hematological Disorders QT Prolongation and Safety in the Indian Population
Current Drug Safety Leptin as a Cardiac Pro-Hypertrophic Factor and its Potential Role in the Development of Heart Failure
Current Pharmaceutical Design Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design